Galectin Therapeutics jumps after positive data from its melanoma treatment.

H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.

Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.

Cerus, Endocyte and Galectin Therapeutics are our big swing trades for Monday. So, how should investors buy and sell?

These under-$10 stocks look ready to break out and trade higher from current levels.

Galectin Therapeutics (GALT) plummeted Tuesday after the company reported poor results in an early-stage trial of its experimental drug for treatment of a fatty liver disease.

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

Shares of drugmaker Intercept Pharmaceuticals (ICPT) are climbing after research firm Summer Street initiated coverage of the shares with a Buy rating and a $650 price target in a note to investors earlier today.

But he thinks the Fed must keep raising interest rates to quell inflation. And he expects continued market volatility.

Britain's new government said it will continue focusing on tax cuts and new borrowing to boost growth even as markets push the pound to a record low against the U.S. dollar.

With interest rates soaring, credit card consumers may be in for a shock